Skip to main content
logo
EQL Pharma AB (publ) (STO:EQL)
Sweden flag Sweden · Delayed Price · Currency is SEK
25.40
+0.85 (3.46%)
At close: Jun 15, 2026

EQL Pharma AB Revenue

In the fiscal year ending March 31, 2026, EQL Pharma AB had annual revenue of 432.66M SEK with 15.83% growth. EQL Pharma AB had revenue of 120.17M in the quarter ending March 31, 2026, with 6.10% growth.

Revenue
432.66M
Revenue Growth
+15.83%
P/S Ratio
1.73
Revenue / Employee
7.21M
Employees
60
Market Cap
750.05M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Mar 31, 2026432.66M59.15M15.83%
Mar 31, 2025373.52M109.35M41.39%
Mar 31, 2024264.17M4.26M1.64%
Mar 31, 2023259.91M-149.84M-36.57%
Mar 31, 2022409.75M230.61M128.73%
Mar 31, 2021 Pro Pro Pro
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Mar 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
BioGaia AB1.54B
Cinclus Pharma Holding AB67.51M
Cereno Scientific AB66.82M
Nanexa AB54.41M
Enzymatica AB53.06M
Newbury Pharmaceuticals AB32.78M
Orexo AB17.80M
Moberg Pharma AB14.59M
Revenue Rankings

EQL Pharma AB News

More News